

RECEIVED  
CENTRAL FAX CENTER

MAR 07 2005

SCHERING-PLOUGH CORPORATION  
LAW DEPARTMENT  
2000 GALLOPING HILL ROAD  
K-6-1, MAIL STOP 1990  
KENILWORTH, NEW JERSEY 07033  
(908) 298-4000

## FACSIMILE TRANSMITTAL SHEET

TO:	FAX NUMBER:
US Patent and Trademark Office	(703) 872-9306
Attn: Examiner Deepak R. Rao	
FROM:	PHONE NUMBER:
Anita W. Magatti	(908) 298-5067
TOTAL NO. OF PAGES INCLUDING COVER	DATE
4	March 7, 2005

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Rosa Scasso-Viola at (908) 298-4080.


## NOTES/COMMENTS:

In re Application of: **Deen Tulshian et al**  
For Patent Entitled: **High Affinity Ligands for Nociceptin Receptor ORL-1**

Filed: 01/21/2004  
Attorney Docket No.: CN0821KD  
Serial No.: 10/761,977

Transmitted herewith are:

- Response to Election Requirement (2 pgs.)
- Certificate of Transmission under 37 CFR 1.8, PTO/SB/97 (1 pg.)
- Fax Cover Sheet (1 pg.)

  
Anita W. Magatti  
Registration No. 29,825

PHONE: (908) 298-5067

FAX: (908) 298-5388

**RECEIVED**  
**CENTRAL FAX CENTER**

MAR 07 2005

Attorney Docket No.: CN0821KD

Application No.: 10/761,977

Filing Date: 01/21/2004

First Named Inventor: Deen Tulshian et al.

PTO/SB/97 (03-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. (703 872-9306 )

on March 7, 2005

Date

  
SignatureAnita W. Magatti, Reg. No. 29,825

Typed or printed name of person signing Certificate

**Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.**

Document(s) being transmitted:

Response to Election Requirement (2 pgs.)

Certificate of Transmission under 37 CFR 1.8, PTO/SB/97 (1 pg.)

Fax Cover Sheet (1 pg.)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 07 2005

PATENT  
CASE CN0821KD**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of:  
Deen Tulshian et alFor Patent For:  
High Affinity Ligands for  
Nociceptin Receptor ORL-1

Serial No.: 10/761,977

Filing Date: January 21, 2004

Examiner: Deepak R. Rao

Art Unit: 1624

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450**RESPONSE TO ELECTION REQUIREMENT**

Sir:

This is in response to the requirement to elect a species mailed on February 9, 2005, a response to which is due March 9, 2005.

Applicants were required to elect a single disclosed species from each of the active agents, i.e., the ORL-1 agonist and the second active agent.

Applicants hereby elect the following species without traverse. For the ORL-1 agonist of formula I, the fifth compound in Table 7 on page 5 is elected, i.e., the

**Certificate of Transmission**

I hereby certify that this correspondence is being facsimile  
transmitted to the Patent and Trademark Office (Fax No. 703-872-9306) on  
March 7, 2005


(Date)

Typed or printed name of person signing this certificate.

Anita W. Magatti


(name)

Signature



-2-

compound having the structure:



For the second active agent, applicants elect the expectorant guaifenesin.

Election of these species does not require amendment of the inventorship.

Applicants reserve the right to file additional applications directed to non-elected subject matter.

Applicants look forward to examination on the merits.

Respectfully submitted,

Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067